Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319977 | 1.00 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL6493867 | 1.00 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL1807296 | 1.00 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL1811917 | 1.00 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8252920 | 0.90 | GRIA1 (0.42) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL2783303 | 0.85 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL20553364 | 0.85 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8867563 | 0.85 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3688366 | 0.83 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3227089 | 0.83 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY RESEARCH FOUNDATION (BURF) (US) | 2004-04-08 | — | — | US | claimed |
| US-7648993-B2 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY (US) | 2010-01-19 | — | — | US | disclosed |
| US-20050171067-A1 | Methods of treating disorders with group I mGluR antagonists | BROWN UNIVERSITY (US) | 2005-08-04 | — | — | US | disclosed |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY RESEARCH FOUNDATION (BURF) (US) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171067-A1 | Methods of treating disorders with group I mGluR antagonists | GRM5, GRIK5, GRM2 | GRIA1 15/4885GRIA2 18/4885GRIA3 14/4885 |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | GRM5, GRIK5, GRM2 | GRIA1 15/4885GRIA2 18/4885GRIA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.